Frontlight ResearchEarly access
Metastatic breast cancer trials in Türkiye
18 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Ankara, Bornova, Bursa, Çankaya, Çapa, Edirne, Izmir, İzmit, Kadiköy, Konak
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - Phase 3Active, not recruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Adapazarı, Ankara, Bakirkoy / Istanbul, Diyarbakır, Istanbul, Izmir, Seyhan, Sihhiye/Ankara
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - Phase 1/2Taking peopleA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Where
- Adana, Ankara, Istanbul, Izmir, Konya, Mersin
- Age
- 18 years and over
- People
- 380 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00 - Phase 3Taking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Ankara, Istanbul, Kocaeli, Sur
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - Phase 2/3Taking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Altındağ, Ankara, Antalya, Bakirkoy / Istanbul, Bornova, Izmir, Erdine, Istanbul, Izmir, Mersin, Samsun
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Ankara, Bakirkoy / Istanbul, Istanbul, Izmir, Mersin
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - Phase 3Not yet taking people in TürkiyeA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Adana, Ankara, Aydin, Edirne, Istanbul, Izmir, Mersin
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - Phase 3Taking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Adana, Ankara, Diyarbakır, Istanbul, Mersin, Rize, Samsun
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - Phase 2Taking peopleTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- Where
- Adana, Ankara, Bağcılar, Seyhan
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00 - Phase 3Taking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Adapazarı, Altındağ-Ankara, Ankara, Çankaya, Istanbul, Kayseri
- Age
- 18 years and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - Phase 3CompletedA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Ankara, Diyarbakır, Edirne, Istanbul, Izmir, Kadiköy, Seyhan, Sihhiye/Ankara
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Ankara, Bağcılar, Izmir
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Ankara, Diyarbakır, Istanbul, Küçükçekmece, Samsun
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Adana, Ankara, Istanbul, Samsun, Stanbul, Yenimahalle
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - Phase 3Taking peoplePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Adana, Ankara, Diyarbakır, Edirne, Istanbul, İzmit, Konya, Mezitli
- Age
- 18 years and over
- People
- 1,180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - No phaseTaking peoplePTEN and Organ-Specific microRNAs in Metastatic Breast Cancer
- Where
- Istanbul
- Age
- 18 years and over
- People
- 160
- Run by
- Atlas University
See details and how to joinNCT07297134 - No phaseTaking peopleImmun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
- Where
- Istanbul
- Age
- 18 years and over
- People
- 30
- Run by
- Istanbul Training and Research Hospital
See details and how to joinNCT07003009 - No phaseTaking peoplePreoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer
- Where
- Ankara
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Ankara Oncology Research and Training Hospital
See details and how to joinNCT05334459